SYNG Pharma Partners with Impact Centre to Develop Endometriosis Diagnostic
Syng Pharmaceuticals is working with the Impact Centre to develop a new non-invasive diagnostic test for endometriosis, an immunologic condition affecting one in ten women.
Previous
Previous
Vasomune Therapeutics Appoints Douglas A. Hamilton as President and Chief Executive Officer
Next
Next